



Overview

Corvidane is developing Corvida™ to treat two diseases with high therapeutic interest and represent multi billion dollar markets:

Atherosclerosis

The build up of fats, cholesterol and cellular waste in arterial walls. Atherosclerotic plaques are a major factor in Heart Attacks and Stroke, the leading causes of death globally.

Nonalcoholic Steatohepatitis (NASH)

An accumulation of excess liver fat accompanied by inflammation and liver cell damage. NASH affects 3-5% of American adults¹ and is the leading cause of liver transplants.

Corvida™ is a fatty acid drug that uses **Omega-7** and **Omega-9 Monounsaturated** fatty acids, not **Omega-3 Polyunsaturated** fatty acids like other fatty acid drugs.

Business Objective

Sell or license Corvida™ to a large pharmaceutical company within 5 years.

Traction

Several pharmaceutical companies have approached Corvidane to express their interest in Corvida™ and their need for additional preclinical data and FDA support for our proposed Regulatory strategy.

Next Steps

Acquire the requisite data via a \$700k Subsidy. Studies of genetically sequenced mice will demonstrate Corvida™'s ability to treat both Atherosclerosis and NASH, while studies of genetically sequenced human plaque tissues will provide additional mechanistic data. Combined, this data forms a performance-prediction model, which will be used alongside previous preclinical studies and FDA precedents in PreIND meetings with the FDA to gain support for our regulatory strategy.

Funding

Amount: \$2,000,000 USD

Tranche 1: \$500k USD (Activates Subsidy, Initial Corvida™ production)

Convertible Notes, 4% Interest with a 20% discount

Term: Convert to equity with Series A funding in 18 Months (estimated)

Tranche 2: \$1,500,000 USD

Non-Dilutive Funding: \$700k USD in Subsidies

Previous Capital: \$2,300,000 USD

Use of Proceeds

Studies: 25% - In Vivo (Animal), In Vitro (Human Tissues), In Silico

Regulatory: 20% - PreIND Meetings (2)

G&A: 25%

Sourcing and Manufacturing: 20%

Legal: 10% Intellectual Property, Corporate

1) "Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030", C. Estes, Q. Anstee, J. Schattenberg, Journal of Hepatology, June 2018